U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT07460843) titled 'Comparison of TB+PB and TB+6SB for Prostate Cancer Diagnosis: A Randomized Controlled Trial' on March 04.
Brief Summary: The goal of this randomized controlled trial (RCT) is to evaluate the diagnostic efficacy of two novel prostate biopsy schemes, including targeted and perilesional biopsy (TB+PB) and combination of sextant-systematic biopsy and targeted biopsy (TB+6SB).
The main questions it aims to answer are:
Does TB+PB promote the accurate diagnosis of clinically significant prostate cancer (csPCa)? Could TB+6SB achieve the non-inferior diagnostic efficacy compared to TB+PB scheme? What's the value of TB+6SB in improving the...